Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Jagannathan
 
NCT04331899
RCTpeginterferonplaceboCOVID-19 mild to moderatesome concern
60/60 inconclusive

    COVID-19 severe or critically meta-analysis

    Kalil (ACTT-3)
     
    NCT04492475
    RCTIFN beta-1aplaceboCOVID-19 severe or criticallysome concern
    487/482 inconclusive
    • inconclusive 1 % decrease in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).